Every 8-K that Amgen Inc (AMGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen Inc. reported second-quarter 2026 results with total revenues up 10% to $10.1 billion and total product sales up 9% to $9,537 million versus the second quarter of 2025. GAAP earnings per share rose 65% from $2.65 to $4.37, while non-GAAP EPS increased 4% from $6.02 to $6.29.
GAAP operating income grew from $2.7 billion to $3.5 billion, expanding GAAP operating margin by 6.5 percentage points to 36.8%. On a non-GAAP basis, operating income increased to $4.6 billion, with operating margin of 48.4%. Free cash flow was $3.5 billion in the quarter, compared with $1.9 billion a year earlier, supported by higher operating cash flow and the absence of a prior-year repatriation tax payment.
Growth was supported by medicines such as Repatha, EVENITY, TEZSPIRE, BLINCYTO and IMDELLTRA, while products including Prolia, Otezla, XGEVA and Enbrel saw lower volume or net selling prices amid biosimilar competition and U.S. pricing dynamics. Amgen ended June 30, 2026 with $14.0 billion in cash and cash equivalents and $57.3 billion of debt, and provided 2026 diluted EPS guidance of $15.80–$17.08 GAAP and $22.30–$23.50 non-GAAP.
Amgen Inc. reports a material cybersecurity incident involving unauthorized activity in data stored in cloud environments hosted by third-party providers. Some company data, including proprietary information, patient protected health information and other records, has been exfiltrated from those cloud systems.
Amgen activated its cybersecurity response plan, implemented containment measures and engaged independent forensic experts, and the investigation remains ongoing. The company has not identified any impact on its products, manufacturing operations, financial reporting systems or ability to meet patient needs, and currently believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations. Amgen is assessing regulatory and legal notification obligations and plans to notify affected patients where required.
Amgen Inc. reported the results of its annual stockholder meeting held on May 19, 2026. All 12 director nominees were elected, each receiving over 390 million votes in favor with substantial margins over votes against.
Stockholders approved the advisory vote on executive compensation, with 399,315,381 votes for and 11,987,682 against, and ratified Ernst & Young LLP as independent registered public accountants for the 2026 fiscal year with 447,904,443 votes for. A stockholder proposal to require an independent board chairman did not pass, receiving 72,902,413 votes for and 338,465,655 votes against.
Amgen Inc. announced a planned chief financial officer transition. Peter H. Griffith, executive vice president and CFO since 2020, will retire from the CFO role effective August 31, 2026 and remain as an executive vice president until his departure in January 2027.
The board approved hiring Thomas Dittrich, age 62, as executive vice president effective July 1, 2026, and he will become executive vice president and CFO on September 1, 2026. His employment offer includes an annual base salary of CHF 1,070,000, eligibility for a target bonus equal to 100% of base salary, and fiscal 2026 long-term equity incentives with a target value of CHF 4,500,000.
To replace compensation forfeited at his current employer, Dittrich will receive a one-time RSU award valued at CHF 4,700,000 and a one-time Swiss cash bonus of CHF 4,000,000, plus a separate two-year retention bonus of CHF 5,800,000. His package also includes relocation benefits, an additional relocation allowance, and a severance agreement providing two times salary and target bonus if terminated by Amgen without cause within two years of his hire date.
Amgen Inc. reported solid first quarter 2026 results, with total revenues rising 6% to $8.6 billion, supported by 4% product sales growth driven by 9% higher volumes. Sixteen products delivered double-digit sales growth and seventeen are tracking at more than $1 billion in annualized sales.
GAAP earnings per share increased from $3.20 to $3.34, while non-GAAP EPS grew from $4.90 to $5.15. GAAP operating income rose from $1.2 billion to $2.7 billion, expanding GAAP operating margin to 32.4%, though non-GAAP operating margin edged down to 45.3%.
The company generated $1.5 billion of free cash flow versus $1.0 billion a year earlier and paid a quarterly dividend of $2.52 per share, up 6%. Management reaffirmed the use of extensive non-GAAP measures and guided 2026 non-GAAP diluted EPS to a range of $21.70–$23.10, compared with GAAP EPS guidance of $15.62–$17.10.
Amgen Inc. announced that David M. Reese, M.D., executive vice president and Chief Technology Officer, will retire from his executive roles effective June 30, 2026. He will remain an executive vice president until that date and receive retirement benefits under existing company plans.
To support Amgen’s focus on combining biology, data science and advanced technologies, the company is redistributing Reese’s responsibilities effective June 1, 2026. James Bradner, M.D., will serve as executive vice president, Research and Development, Artificial Intelligence and Data; Sean Bruich will become senior vice president and Chief Technology Officer; and Murdo Gordon will lead Amgen Global Markets and Policy as executive vice president. These changes are intended to deepen the integration of science and technology across research, medical, commercial and policy functions.
Amgen Inc. issued and sold four series of senior unsecured notes, receiving net proceeds of $3,961,495,000 from the offering. These notes were issued under an existing shelf registration and an indenture originally dated May 22, 2014.
The company sold $1,000,000,000 of 4.200% Senior Notes due 2031, $1,750,000,000 of 4.850% Senior Notes due 2036, $500,000,000 of 5.500% Senior Notes due 2046 and $750,000,000 of 5.650% Senior Notes due 2056. Interest is payable in cash semi-annually on February 19 and August 19, beginning August 19, 2026.
The notes rank equally with Amgen’s other existing and future senior unsecured debt, are senior to subordinated debt, are effectively subordinated to subsidiary obligations and are subordinated to secured obligations to the extent of pledged assets. Upon a defined change of control triggering event, holders may require Amgen to repurchase their notes at 101% of principal plus accrued interest.
Amgen Inc. furnished an 8-K to share that it has issued a press release with unaudited results for the fourth quarter and full year ended December 31, 2025, along with its financial position as of that date. The press release includes several non-GAAP measures such as non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses, including non-GAAP cost of sales, R&D, and selling, general and administrative expenses, each reconciled to the nearest GAAP figure. Amgen also presents Free Cash Flow, defined as GAAP operating cash flow minus capital expenditures, and EBITDA and a debt leverage ratio based on GAAP total debt and EBITDA. The company explains it uses these metrics internally for planning, performance evaluation, and incentive compensation and believes they help investors assess ongoing operations and liquidity. The non-GAAP information is described as supplemental to, and not a replacement for, GAAP results and is furnished, not filed, under the Exchange Act.
Amgen Inc. filed an 8-K stating it signed a Termination Agreement with Kyowa Kirin Co., Ltd. to end their License and Collaboration Agreement dated June 1, 2021. The termination will take effect once regulatory approval is received, meaning the prior collaboration will formally conclude only after that approval.
Amgen Inc. furnished an 8-K announcing its third quarter 2025 results, with the full press release provided as Exhibit 99.1. The release includes unaudited operating results for the three and nine months ended September 30, 2025 and the company’s financial position as of that date.
Amgen presented non-GAAP metrics alongside GAAP, including non-GAAP EPS, operating income, operating margin, tax rate, operating expenses (and sub-components), and Free Cash Flow, with reconciliations to GAAP included. Adjustments cover acquisition-related expenses, restructuring and cost savings initiatives, certain investment gains/losses, specified legal items, and related tax effects. The information is furnished, not filed, under Item 2.02.